SDZ ICT 322Alternative Names: SDZ 214322
Latest Information Update: 03 Feb 1997
At a glance
- Originator Novartis
- Class Antiemetics
- Mechanism of Action Serotonin 3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Nausea and vomiting
Most Recent Events
- 03 Feb 1997 No-Development-Reported for Emesis in Switzerland (Unknown route)